Education
About Us
Working with TipRanks
Follow Us
Eupraxia Pharmaceuticals, Inc. (EPRX)
:EPRX
RESEARCH TOOLSreports
Total Valuation
Eupraxia Pharmaceuticals has a market cap or net worth of $144.13M. The enterprise value is $156.59M.
Market Cap$144.13M
Enterprise Value$156.59M
Share Statistics
Eupraxia Pharmaceuticals has 35,849,354 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding35,849,354
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Eupraxia Pharmaceuticals’s return on equity (ROE) is -16.87 and return on invested capital (ROIC) is -423.20%.
Return on Equity (ROE)-16.87
Return on Assets (ROA)-1.40
Return on Invested Capital (ROIC)-423.20%
Return on Capital Employed (ROCE)-31.36
Revenue Per Employee0.00
Profits Per Employee-1.13M
Employee Count33
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Eupraxia Pharmaceuticals is -3.47. Eupraxia Pharmaceuticals’s PEG ratio is -0.11.
PE Ratio-3.47
PS Ratio―
PB Ratio58.51
Price to Fair Value58.51
Price to FCF-4.63
Price to Operating Cash Flow-4.64
PEG Ratio-0.11
Income Statement
In the last 12 months, Eupraxia Pharmaceuticals had revenue of 0.00 and earned -37.39M in profits. Earnings per share was -1.58.
Revenue0.00
Gross Profit-209.91K
Operating Income-36.90M
Pretax Income-39.18M
Net Income-37.39M
EBITDA-37.40M
Earnings Per Share (EPS)-1.58
Cash Flow
In the last 12 months, operating cash flow was -27.03M and capital expenditures -94.30K, giving a free cash flow of -18.87M billion.
Operating Cash Flow-27.03M
Free Cash Flow-18.87M
Free Cash Flow per Share-0.53
Dividends & Yields
Eupraxia Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.99
52-Week Price Change35.09%
50-Day Moving Average3.59
200-Day Moving Average3.03
Relative Strength Index (RSI)62.40
Average Volume (3m)10.45K
Important Dates
Eupraxia Pharmaceuticals upcoming earnings date is May 8, 2025, TBA Not Confirmed.
Last Earnings DateMar 20, 2025
Next Earnings DateMay 8, 2025
Ex-Dividend Date―
Financial Position
Eupraxia Pharmaceuticals as a current ratio of 0.78, with Debt / Equity ratio of 0.98%
Current Ratio0.78
Quick Ratio0.78
Debt to Market Cap0.11
Net Debt to EBITDA0.40
Interest Coverage Ratio-23.36
Taxes
In the past 12 months, Eupraxia Pharmaceuticals has paid -89.67K in taxes.
Income Tax-89.67K
Effective Tax Rate<0.01
Enterprise Valuation
Eupraxia Pharmaceuticals EV to EBITDA ratio is -3.06, with an EV/FCF ratio of -4.09.
EV to Sales0.00
EV to EBITDA-3.06
EV to Free Cash Flow-4.09
EV to Operating Cash Flow-4.11
Balance Sheet
Eupraxia Pharmaceuticals has $8.66M in cash and marketable securities with C$11.94M in debt, giving a net cash position of -$8.57M billion.
Cash & Marketable Securities$8.66M
Total DebtC$11.94M
Net Cash-$8.57M
Net Cash Per Share-$0.24
Tangible Book Value Per Share$0.05
Margins
Gross margin is 46.38%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin46.38%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Eupraxia Pharmaceuticals is $12.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$12.00
Price Target Upside211.63% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast―